Literature DB >> 16216233

Epithelial membrane protein-2 regulates surface expression of alphavbeta3 integrin in the endometrium.

Madhuri Wadehra1, Ashley Forbes, Natasha Pushkarna, Lee Goodglick, Lynn K Gordon, Carmen J Williams, Jonathan Braun.   

Abstract

The four-transmembrane protein epithelial membrane protein-2 (EMP2) was recently identified as an endometrial protein necessary for blastocyst implantation, but the mechanism of this role is uncertain. In other cell types, EMP2 controls delivery of certain classes of proteins to the cell surface, including various integrin isoforms (a class of receptors implicated in endometrial-blastocyst interaction). Since alphavbeta3 integrin is an important endometrial molecule involved in blastocyst interaction, we evaluated the role of EMP2 in modulating integrin expression in the HEC1A endometrial cell line and endometrial epithelium in vivo. Elevation of EMP2 expression in HEC1A cells selectively increased the expression of alphavbeta3 integrin on the plasma membrane and was functional as judged by increased cell binding to an alphavbeta3 ligand, fibronectin. Conversely, reduction in EMP2 expression using an EMP2 specific ribozyme decreased the cell alphavbeta3 surface expression. The influence of EMP2 on alphavbeta3 integrin was also observed in vivo as reduction of EMP2 using ribozymes or short hairpin RNA diminished alphavbeta3 integrin expression in glandular and luminal uterine epithelium. Colocalization and coimmunoprecipitation studies suggested that EMP2 and alphavbeta3 integrin predominantly exist in a physically associated state. This study demonstrates for the first time the influence of EMP2 on alphavbeta3 surface expression and suggests that surface trafficking of integrin alphavbeta3 by EMP2 during the window of implantation may be a mechanism for its requirement in endometrial-blastocyst interaction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16216233     DOI: 10.1016/j.ydbio.2005.09.003

Source DB:  PubMed          Journal:  Dev Biol        ISSN: 0012-1606            Impact factor:   3.582


  34 in total

1.  Anti-EMP2 diabody blocks epithelial membrane protein 2 (EMP2) and FAK mediated collagen gel contraction in ARPE-19 cells.

Authors:  Shawn A Morales; David G Telander; Sergey Mareninov; Agnes Nagy; Madhuri Wadehra; Jonathan Braun; Lynn K Gordon
Journal:  Exp Eye Res       Date:  2012-06-19       Impact factor: 3.467

2.  Functional consequences of interactions between FAK and epithelial membrane protein 2 (EMP2).

Authors:  Shawn A Morales; Sergey Mareninov; Paige Coulam; Madhuri Wadehra; Lee Goodglick; Jonathan Braun; Lynn K Gordon
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-06-03       Impact factor: 4.799

Review 3.  Regulation of FAK Activity by Tetraspan Proteins: Potential Clinical Implications in Cancer.

Authors:  Yu Qin; Shabnam Mohandessi; Lynn Gordon; Madhuri Wadehra
Journal:  Crit Rev Oncog       Date:  2015

Review 4.  Review of the GAS3 Family of Proteins and their Relevance to Cancer.

Authors:  Negin Ashki; Lynn Gordon; Madhuri Wadehra
Journal:  Crit Rev Oncog       Date:  2015

5.  Epithelial membrane protein 2 controls VEGF expression in ARPE-19 cells.

Authors:  Shawn A Morales; David G Telander; Deanna Leon; Krisztina Forward; Jonathan Braun; Madhuri Wadehra; Lynn K Gordon
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-03-28       Impact factor: 4.799

6.  Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer.

Authors:  Maoyong Fu; Erin L Maresh; Robert A Soslow; Mohammad Alavi; Vei Mah; Qin Zhou; Alexia Iasonos; Lee Goodglick; Lynn K Gordon; Jonathan Braun; Madhuri Wadehra
Journal:  Clin Cancer Res       Date:  2010-08-01       Impact factor: 12.531

7.  Genomic profiling of genes contributing to metastasis in a mouse model of thyroid follicular carcinoma.

Authors:  Changxue Lu; Alok Mishra; Yuelin J Zhu; Paul Meltzer; Sheue-Yann Cheng
Journal:  Am J Cancer Res       Date:  2011-01-01       Impact factor: 6.166

8.  Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer.

Authors:  Maoyong Fu; Erin L Maresh; Gustavo F Helguera; Meagan Kiyohara; Yu Qin; Negin Ashki; Tracy R Daniels-Wells; Najib Aziz; Lynn K Gordon; Jonathan Braun; Yahya Elshimali; Robert A Soslow; Manuel L Penichet; Lee Goodglick; Madhuri Wadehra
Journal:  Mol Cancer Ther       Date:  2014-01-21       Impact factor: 6.261

9.  Epithelial membrane protein 2 governs transepithelial migration of neutrophils into the airspace.

Authors:  Wan-Chi Lin; Kymberly M Gowdy; Jennifer H Madenspacher; Rachel L Zemans; Kazuko Yamamoto; Miranda Lyons-Cohen; Hideki Nakano; Kyathanahalli Janardhan; Carmen J Williams; Donald N Cook; Joseph P Mizgerd; Michael B Fessler
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

10.  Mutations in EMP2 cause childhood-onset nephrotic syndrome.

Authors:  Heon Yung Gee; Shazia Ashraf; Xiaoyang Wan; Virginia Vega-Warner; Julian Esteve-Rudd; Svjetlana Lovric; Humphrey Fang; Toby W Hurd; Carolin E Sadowski; Susan J Allen; Edgar A Otto; Emine Korkmaz; Joseph Washburn; Shawn Levy; David S Williams; Sevcan A Bakkaloglu; Anna Zolotnitskaya; Fatih Ozaltin; Weibin Zhou; Friedhelm Hildebrandt
Journal:  Am J Hum Genet       Date:  2014-05-08       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.